Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: A single institutional review of 77 patients from China

Neuro-Oncology

Volumn 14, Issue 1, 2012, Pages 109-116

  Li, Shouwei ^a,c   Yan, Changxiang ^a   Huang, Lei ^b   Qiu, Xiaoguang ^b   Wang, Zhongcheng ^c   Jiang, Tao ^b,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anaplastic oligodendroglial tumor; IDH1 mutation; LOH 1p and 19q; MGMT; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; KI 67 ANTIGEN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHINA; CHROMOSOME 19Q; CHROMOSOME 1P; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OLIGODENDROGLIA; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; REOPERATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CHINA; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; KI-67 ANTIGEN; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84863049390     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor185     Document Type: Article

References (29)

1. Bromberg JE, van den Bent MJ. Oligodendrogliomas: Molecular biology and treatment. Oncologist. 2009;14:155-163.
2. Blakeley J, Grossman S. Anaplastic oligodendroglioma. Curr Treat Options Neurol. 2008;10:295-307.
3. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-2714. (Pubitemid 46630566)
4. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-2722. (Pubitemid 46630567)
5. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007;66:545-551. (Pubitemid 46869696)
6. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988;23:360-364. (Pubitemid 18098242)
7. Kim L, Hochberg FH, Thornton AF, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg. 1996;85:602-607. (Pubitemid 26315193)
8. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
9. Chernova OB, Barnett GH, Cowell JK. Rapid detection of allelic losses in brain tumours using microsatellite repeat markers and high-performance liquid chromatography. Br J Cancer. 2003;88:1889-1893. (Pubitemid 36829664)
10. Kleymenova E, Walker CL. Determination of loss of heterozygosity in frozen and paraffin embedded tumors by denaturating highperformance liquid chromatography (DHPLC). J Biochem Biophys Methods. 2001;47:83-90. (Pubitemid 32155478)
11. Huang L, Jiang T, Yuan F, et al. Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors. Clin Neurol Neurosurg. 2008;110:1020-1024.
12. Huang L, Jiang T, Yuan F, et al. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: A clinicopathological study. Neuropathol Appl Neurobiol. 2009;35:367-379.
13. van den BentMJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597-1604.
14. Kouwenhoven MC, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol. 2009;11:737-746.
15. Parkinson JF, Afaghi V, Payne CA, et al. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre. J Clin Neurosci. 2011;18:329-333.
16. Shirai K, Suzuki Y, Okamoto M, et al. Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma. J Radiat Res (Tokyo). 2010;51:589-594.
17. Yang LS, Huang FP, Zheng K, et al. Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: A single institutional review of 70 patients. J Neurooncol. 2010;100:113-120.
18. Soffietti R. Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin Pharmacother. 2004;5:295-306. (Pubitemid 38219856)
19. Dehghani F, SchachenmayrW, Laun A, et al. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases. Acta Neuropathol. 1998;95:493-504.
20. Mikkelsen T, Doyle T, Anderson J, et al. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol. 2009;92:57-63.
21. Vogelbaum MA, Berkey B, Peereboom D, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009;11:167-175.
22. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149-1153.
23. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352: 997-1003. (Pubitemid 40349502)
24. Mollemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer. 2005;113:379-385. (Pubitemid 40038704)
25. Ueki K, Nishikawa R, Nakazato Y, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res. 2002;8:196-201. (Pubitemid 34101478)
26. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108:49-56. (Pubitemid 38961073)
27. Jeon YK, Park K, Park CK, et al. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: A clinicopathological study using fluorescence in situ hybridization. Neuropathology. 2007;27:10-20. (Pubitemid 46146609)
28. Kujas M, Lejeune J, Benouaich-Amiel A, et al. Chromosome 1p loss: A favorable prognostic factor in low-grade gliomas. Ann Neurol. 2005;58:322-326. (Pubitemid 41098891)
29. Yakut T, Gutenberg A, Bekar A, et al. Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. Oncol Rep. 2007;17:1037-1043.